Famotidine Adjunctive Pharmacotherapy of Schizophrenia

Rosse, Richard B.; Kendrick, Kathie; Tsui, Lorraine C.; Fay-McCarthy, Maureen; Collins, Joseph P.; Rosenberg, Paul B.; Wyatt, Richard Jed; Deutsch, Stephen I.

doi:10.1097/00002826-199508000-00009

Cited by 16 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decrease in H1 histamine receptor density in the frontal cortex of brains from patients with chronic schizophrenia has also been reported [Nakai et al, 1991], and the concentration of the methylated histamine metabolite N τ ‐methylhistamine was significantly increased in the cerebrospinal fluid of chronic schizophrenic patients with psychogenic polydipsia–polyuria as compared to patients without polydipsia–polyuria [Prell et al, 1995]. Finally, clinical studies have suggested that H2 histamine receptor antagonists such as famotidine may be useful adjunctive therapy in the treatment of subgroups of schizophrenic patients [Deutsch et al, 1993; Kaminsky et al, 1990; Rosse et al, 1995].…”

Section: Introductionmentioning

confidence: 99%

Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia

Yan

Szumlanski

Rice³

et al. 2000

Am. J. Med. Genet.

View full text Add to dashboard Cite

Histamine is a central nervous system (CNS) neurotransmitter that has been implicated in the pathophysiology of schizophrenia. Histamine N-methyltransferase (HNMT) terminates the neurotransmitter actions of histamine in the mammalian CNS, and levels of HNMT activity in human tissues are controlled, in part, by inheritance. A common C314T polymorphism in the HNMT gene causes a Thr105Ile change in encoded amino acid. The T314 allele results in decreased levels of both HNMT enzyme activity and immunoreactive protein. There is also a polymorphic CA repeat in intron 5 of the HNMT gene. The frequencies of alleles for the functional C314T polymorphism and the polymorphic CA repeat were compared between 171 schizophrenia cases and 171 ethnically matched controls to test for possible disease association. No significant difference was found between the two groups in the frequency of the T314 allele in patients with schizophrenia and controls (0.068 vs. 0.078, respectively). Allele frequencies for the polymorphic HNMT CA repeat also failed to show significant differences between cases and matched controls.

show abstract

Section: Introductionmentioning

confidence: 99%

Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia

Yan

Szumlanski

Rice³

et al. 2000

Am. J. Med. Genet.

View full text Add to dashboard Cite

show abstract

“…5,6 (pooled N = 2) and 6 small open studies [7][8][9][10][11][12] (pooled N = 75) indicated benefits with famotidine augmentation in antipsychotic-refractory schizophrenia. 2.…”

Section: Clinical Pointsmentioning

confidence: 99%

“…This patient also had schizophrenia, and the deficit symptoms that were present improved after the initiation of famotidine, worsened when famotidine was withdrawn, and improved again when famotidine was reintroduced. Rosse et al 6 reported that a treatment-resistant patient with chronic undifferentiated schizophrenia also improved dramatically with famotidine (40-100 mg/d) across 10 months of treatment.…”

mentioning

confidence: 99%

Famotidine Augmentation in Schizophrenia: Hope or Hype?

Andrade

2013

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Pathological hypersecretory conditions of Zollinger-Ellison syndrome and multiple Endocrine Adenomas are also managed by Famotidine [4,5]. By giving Famotidine there are reports of improvement in Schizophrenic symptoms in patients [6][7][8]. It is also used in patients on NSAIDs therapy to prevent the occurrence of peptic ulcers.…”

Section: Introductionmentioning

confidence: 99%

Determination of Chemical Stability of Various Famotidine Dosage Forms by UV –Visible Spectrophotometric Method and Data Analysis by R-GUI Stability Software

Hassan

Zaheer

Muhammad

et al. 2015

J. Basic Appl. Sci.

View full text Add to dashboard Cite

H2 receptor antagonists are still the first line of therapy in treating gastro esophageal reflux diseases as well as other ulcers of the upper gastrointestinal tract. Accelerated stability studies of different brands of Famotidine tablets (20mg) and suspension(10mg/5ml),both liquid and dry, were carried out at 40 o C ± 2 o C (Temperature) and 75% R.H. ± 5% R.H. The assay of tablets was conducted by both HPLC and UV/Visible Spectrophotometric methods whereas for suspensions only UV/Visible Spectrophotometric method was used. The tests were conducted at 0, 1, 3 and 6 months as per guidelines of ICH for accelerated studies. The results of physical tests indicated that the dissolution of tablet decreases in all cases with time whereas disintegration of all brands was found within 15 minutes throughout the course of study while the hardness demonstrated to be decline with time. Kinetic treatment to determine rate constants and shelf lives indicated that dry suspension was more stable than liquids while the tablets showed stability for three years which was parallel to their claimed expiry. Among tablets, brand A was the most stable and among suspensions, brand C showed the longest stability. The stability studies were also carried out by using a software R-Gui (version 2.13) and results were compared with manually calculated results.

show abstract

Famotidine Adjunctive Pharmacotherapy of Schizophrenia

Cited by 16 publications

References 0 publications

Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia

Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia

Famotidine Augmentation in Schizophrenia: Hope or Hype?

Determination of Chemical Stability of Various Famotidine Dosage Forms by UV –Visible Spectrophotometric Method and Data Analysis by R-GUI Stability Software

Contact Info

Product

Resources

About